- Home
- GH
as 07-25-2025 4:00pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Upcoming Earnings Alert:
Get ready for potential market movements as Guardant Health Inc. GH prepares to release earnings report on 30 Jul 2025.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $55.11 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.14 - $53.42 | Next Earning Date: | 07-30-2025 |
| Revenue: | $773,996,000 | Revenue Growth: | 28.20% |
| Revenue Growth (this year): | 23.37% | Revenue Growth (next year): | 21.31% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | Jun 18 '25 | Sell | $49.47 | 3,213 | $158,947.11 | 7,190 | |
| CLARK IAN T | GH | Director | Jun 17 '25 | Sell | $48.38 | 6,672 | $322,818.72 | 9,851 | |
| POTTER MYRTLE S | GH | Director | Jun 12 '25 | Sell | $49.70 | 2,626 | $130,512.20 | 18,180 | |
| Joyce Meghan V. | GH | Director | Jun 12 '25 | Sell | $47.22 | 3,337 | $157,573.14 | 11,150 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | Jun 5 '25 | Sell | $50.06 | 119,284 | $5,974,363.95 | 2,147,309 | |
| Kalia Kumud | GH | Chief Information Officer | Jun 3 '25 | Sell | $46.39 | 4,000 | $185,561.60 | 18,765 | |
| Joyce Meghan V. | GH | Director | Jun 2 '25 | Sell | $41.66 | 100 | $4,166.00 | 11,150 | |
| Tariq Musa | GH | Director | May 19 '25 | Sell | $40.04 | 116 | $4,644.64 | 7,190 | |
| Talasaz AmirAli | GH | Co-Chief Executive Officer | May 1 '25 | Sell | $50.20 | 120,716 | $5,936,572.01 | 2,147,309 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
StockStory
a month ago
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Zacks
a month ago
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
Investor's Business Daily
a month ago
Medical Services Name Flirts With A Buy Point
MT Newswires
a month ago
Guardant Health Insider Sold Shares Worth $322,819, According to a Recent SEC Filing
Zacks
a month ago
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
Investor's Business Daily
a month ago
Dow Jones Futures Rise As Trump Buys Time For Iran; Tesla Robotaxi To Have Safety Monitor
StockStory
a month ago
3 of Wall Street’s Favorite Stocks Facing Headwinds
StockStory
2 months ago
2 Mooning Stocks Worth Your Attention and 1 to Be Wary Of
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.